More Articles Back to Article
- WHO to convene emergency meeting on coronavirus cases in China
- Novartis gains EU approval for MS treatment Mayzent
- Label expansion approved in Europe for Darzalex, triple-drug combo in MM treatment
- Lymphoma treatment gains conditional approval in Europe
- FDA sends warning letter to Chinese OTC drug firm
EU OKs Merck, MSD's Keytruda combo as first-line kidney cancer therapy
The European Commission has approved Merck and MSD's Keytruda, in combination with Pfizer's Inlyta, or axitinib, as a first-line treatment for patients with renal cell carcinoma. In a late-stage trial, the combination drug reduced death risk in patients with RCC by 47% versus Pfizer's Sutent, or sunitinib. PharmaPhorum (UK) (9/5)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!